Actualités des entreprises tech européennes

Les annonces officielles conservent leur titre et leur langue d’origine.

25 résultats

Actualité d’entreprise22 oct. 2026EN

Pharming Group announces third quarter 2026 revenues above market expectations

Pharming Group N.V.Company newsroom

Actualité d’entreprise14 oct. 2026EN

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Pharming Group N.V.Company newsroom

Actualité d’entreprise29 sept. 2026EN

Pharming announces CEO transition

Pharming Group N.V.Company newsroom

Actualité d’entreprise25 sept. 2026EN

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Pharming Group N.V.Company newsroom

Actualité d’entreprise22 sept. 2026EN

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Pharming Group N.V.Company newsroom

Actualité d’entreprise11 sept. 2026EN

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Pharming Group N.V.Company newsroom

Actualité d’entreprise9 sept. 2026EN

Pharming Group to participate in September investor conferences

Pharming Group N.V.Company newsroom

Actualité d’entreprise13 août 2026EN

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

Pharming Group N.V.Company newsroom

Actualité d’entreprise4 août 2026EN

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

Pharming Group N.V.Company newsroom

Actualité d’entreprise30 juil. 2026EN

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

Pharming Group N.V.Company newsroom

Actualité d’entreprise16 juil. 2026EN

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

Pharming Group N.V.Company newsroom

Actualité d’entreprise4 juin 2026EN

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming Group N.V.Company newsroom

Actualité d’entreprise2 juin 2026EN

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

Pharming Group N.V.Company newsroom

Actualité d’entreprise28 mai 2026EN

Pharming Group announces results of 2026 Annual General Meeting of Shareholders

Pharming Group N.V.Company newsroom

Actualité d’entreprise22 mai 2026EN

European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

Pharming Group N.V.Company newsroom

Actualité d’entreprise7 mai 2026EN

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

Pharming Group N.V.Company newsroom

Actualité d’entreprise7 mai 2026EN

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

Pharming Group N.V.Company newsroom

Actualité d’entreprise23 avr. 2026EN

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group N.V.Company newsroom

Actualité d’entreprise16 avr. 2026EN

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Pharming Group N.V.Company newsroom

Actualité d’entreprise7 avr. 2026EN

Pharming Group to participate in April investor conferences

Pharming Group N.V.Company newsroom

Analyses

Rechercher des entreprises et des analyses